Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02992288 · ClinicalTrials.gov registry record · Phase 2
A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Reduced Ejection Fraction
A Phase 2 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 2
- Development phase
- 427
- Enrollment target
NCT02992288 is a Phase 2 study that has completed, run by Bayer. The registered enrollment target is 427 participants.
The verdict
NCT02992288, a Phase 2 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 427 participants
- Enrollment target
Study Summary
The objective of the study is to find the optimal dose of once daily oral neladenoson bialanate (BAY 1067197) when given in addition to standard therapy for heart failure with reduced ejection fraction (HFrEF).
Interventions
- DRUG Neladenoson bialanate (BAY1067197)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 427 participants |
| Start Date | 2017-02-22 |
| Est. Completion | 2018-05-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02992288
The ClinicalTrials.gov registry entry for NCT02992288 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 427 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Neladenoson bialanate (BAY1067197) is the first listed.
NCT02992288 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02992288 about?
NCT02992288 is a clinical study titled "A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Reduced Ejection Fraction". The objective of the study is to find the optimal dose of once daily oral neladenoson bialanate (BAY 1067197) when given in addition to standard therapy for heart failure with reduced ejection fraction (HFrEF).
What is the current status of trial NCT02992288?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 427 participants. The study started on 2017-02-22. Estimated completion is 2018-05-16.
What interventions are being tested in trial NCT02992288?
The interventions under investigation include: Neladenoson bialanate (BAY1067197) (DRUG).
Who is sponsoring clinical trial NCT02992288?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.